These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38397992)

  • 81. Real-world effectiveness of dupilumab in patients with asthma: Findings from the US ADVANTAGE study.
    Blaiss M; Bleecker ER; Jacob-Nara J; Nair R; Duh MS; Wang Z; Stanford RH; Soler X; Hardin M; Ye M; Khanal A; Borsos K
    Ann Allergy Asthma Immunol; 2024 Apr; 132(4):463-468.e1. PubMed ID: 37967668
    [TBL] [Abstract][Full Text] [Related]  

  • 82. The Role of Fractional Exhaled Nitric Oxide in Diagnosing Asthmatic Type 2 Chronic Rhinosinusitis With Nasal Polyps.
    Park JA; Cha H; Yang SK; Ryu HT; Kim DW; Hong SN; Yang MS; Kim DW
    Am J Rhinol Allergy; 2023 Sep; 37(5):524-530. PubMed ID: 37160729
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases.
    Hamilton JD; Harel S; Swanson BN; Brian W; Chen Z; Rice MS; Amin N; Ardeleanu M; Radin A; Shumel B; Ruddy M; Patel N; Pirozzi G; Mannent L; Graham NMH
    Clin Exp Allergy; 2021 Jul; 51(7):915-931. PubMed ID: 34037993
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Dupilumab effectiveness for the treatment of patients with concomitant atopic dermatitis and chronic rhinosinusitis with nasal polyposis.
    Napolitano M; Maffei M; Patruno C; Leone CA; Di Guida A; Potestio L; Scalvenzi M; Fabbrocini G
    Dermatol Ther; 2021 Nov; 34(6):e15120. PubMed ID: 34472171
    [TBL] [Abstract][Full Text] [Related]  

  • 85. When sequential use of mepolizumab and dupilumab in a severe atopic eosinophilic asthmatic questions the role of eosinophils in mediating the clinical expression of the disease: a case report.
    Sabbe M; Schleich F; Janssens P; Louis R
    J Med Case Rep; 2024 Jan; 18(1):63. PubMed ID: 38291489
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Real-world evidence for the effectiveness and safety of dupilumab in patients with CRSwNP after 1 year of therapy.
    Albrecht T; Sailer MM; Capitani F; van Schaik C; Löwenheim H; Becker S
    World Allergy Organ J; 2023 May; 16(5):100780. PubMed ID: 37234094
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Dupilumab efficacy in patients with chronic rhinosinusitis with nasal polyps with and without allergic rhinitis.
    Peters AT; Wagenmann M; Bernstein JA; Khan AH; Nash S; Jacob-Nara JA; Siddiqui S; Rowe PJ; Deniz Y
    Allergy Asthma Proc; 2023 Jul; 44(4):265-274. PubMed ID: 37480206
    [No Abstract]   [Full Text] [Related]  

  • 88. Systemic treatments for eczema: a network meta-analysis.
    Sawangjit R; Dilokthornsakul P; Lloyd-Lavery A; Lai NM; Dellavalle R; Chaiyakunapruk N
    Cochrane Database Syst Rev; 2020 Sep; 9(9):CD013206. PubMed ID: 32927498
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Clinical outcomes of dupilumab therapy in chronic rhinosinusitis with nasal polyps in a Canadian tertiary care rhinology practice.
    Grose E; Li AY; Lee JM
    Allergy Asthma Clin Immunol; 2023 Mar; 19(1):26. PubMed ID: 36998065
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Chinese Expert Consensus on the Use of Biologics in Patients with Chronic Rhinosinusitis (2022, Zhuhai).
    Hong HY; Chen TY; Yang QT; Sun YQ; Chen FH; Lou HF; Wang HT; Yu RL; An YF; Liu F; Wang TS; Lu MP; Qiu QH; Wang XD; Chen JJ; Meng CD; Xie ZH; Meng J; Zeng M; Xu CL; Wang Y; Yang YC; Zhang WT; Tang J; Yang YL; Xu R; Yu GD; Shi ZH; Wei X; Ye HP; Sun YN; Yu SQ; Zhang TH; Yong J; Hang W; Xu YT; Xu Y; Tan GL; Sun N; Yang G; Li YJ; Ye J; Zuo KJ; Zhang LQ; Wang XY; Yang AN; Xu YX; Liao W; Fan YP; Li HB
    ORL J Otorhinolaryngol Relat Spec; 2023; 85(3):128-140. PubMed ID: 37019094
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Dupilumab Efficacy in Patients Stratified by Baseline Treatment Intensity and Lung Function.
    Pavord ID; Siddiqui S; Papi A; Corren J; Sher LD; Bardin P; Langton D; Park HS; Rice MS; Deniz Y; Rowe P; Staudinger HW; Patel N; Ruddy M; Graham NMH; Teper A
    J Asthma Allergy; 2020; 13():701-711. PubMed ID: 33364789
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Global influence of dupilumab on Quality of Life in a severe asthma patient with T2 multimorbidities: a case report on atopic dermatitis, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis.
    Colque-Bayona M; Hernández-Cano N; Tomás-Pérez M; Caballero T; Quirce S; Domínguez-Ortega J
    J Asthma; 2024 Jul; 61(7):762-765. PubMed ID: 38152869
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Differential nasal swab cytology represents a valuable tool for therapy monitoring but not prediction of therapy response in chronic rhinosinusitis with nasal polyps treated with Dupilumab.
    Danisman Z; Linxweiler M; Kühn JP; Linxweiler B; Solomayer EF; Wagner M; Wagenpfeil G; Schick B; Berndt S
    Front Immunol; 2023; 14():1127576. PubMed ID: 37180133
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Dupilumab efficacy and safety in Japanese patients with uncontrolled, moderate-to-severe asthma in the phase 3 LIBERTY ASTHMA QUEST study.
    Tohda Y; Nakamura Y; Fujisawa T; Ebisawa M; Arima K; Miyata M; Takahashi Y; Rice MS; Deniz Y; Rowe P; Patel N; Graham NMH; Teper A
    Allergol Int; 2020 Oct; 69(4):578-587. PubMed ID: 32444306
    [TBL] [Abstract][Full Text] [Related]  

  • 95. [A clinical observational study on the preliminary effect of dupilumab in the treatment of severe asthma].
    Li Y; Lin HM; Zhang XX; Ou CX; Xie JX; Zhang QL
    Zhonghua Jie He He Hu Xi Za Zhi; 2023 Sep; 46(9):909-915. PubMed ID: 37670644
    [No Abstract]   [Full Text] [Related]  

  • 96. Biologics in severe uncontrolled chronic rhinosinusitis with nasal polyps: A bicentric experience.
    Bellocchi G; Loperfido A; Passali FM; Millarelli S; Velletrani G; Perla M; Di Michele L; Di Girolamo S
    Acta Biomed; 2023 Oct; 94(5):e2023227. PubMed ID: 37850768
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Severe chronic rhinosinusitis treated with dupilumab, a real-life analysis of early effectiveness.
    Mocellin D; Ioppi A; Gaglio G; Pennacchi A; Bertolini M; Tirrito A; Guastini L; Bagnasco D; Passalacqua G; Peretti G; Canevari FRM
    Eur Rev Med Pharmacol Sci; 2023 Aug; 27(15):7324-7336. PubMed ID: 37606141
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Chronic Rhinosinusitis with Nasal Polyps and Asthma.
    Laidlaw TM; Mullol J; Woessner KM; Amin N; Mannent LP
    J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1133-1141. PubMed ID: 33065369
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Indirect Treatment Comparison of Biologics in Chronic Rhinosinusitis with Nasal Polyps.
    Peters AT; Han JK; Hellings P; Heffler E; Gevaert P; Bachert C; Xu Y; Chuang CC; Neupane B; Msihid J; Mannent LP; Guyot P; Kamat S
    J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2461-2471.e5. PubMed ID: 33548517
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Clinical Remission in Patients Affected by Severe Eosinophilic Asthma on Dupilumab Therapy: A Long-Term Real-Life Study.
    Quarato CMI; Tondo P; Lacedonia D; Soccio P; Fuso P; Sabato E; Hoxhallari A; Foschino Barbaro MP; Scioscia G
    J Clin Med; 2024 Jan; 13(1):. PubMed ID: 38202298
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.